DaVita: An Essential Provider of Dialysis Services

Published on May 20, 2022

Note to readers: This article is the second in a two-part series on the dialysis industry. For background information that will be helpful while reading this article, please read Kidney Failure and the Dialysis Industry which was published last week. In order to keep this article focused on DaVita, the discussion will assume that the reader is aware of the nature of end-stage renal disease and the options that are available to treat it.

Introduction

DaVita is one of the leading kidney care providers in the United States. The company serves approximately 203,100 patients with chronic kidney failure and end-stage renal disease (ESRD) through a network of 2,809 outpatient dialysis centers located in 46 states and the District of Columbia.  DaVita also delivers inpatient dialysis services in approximately 850 hospitals and the company provides training, equipment, and logistical support to patients who prefer to perform dialysis treatments at home.1

At the end of 2019, 809,103 individuals in the United States had ESRD. Of this population, 492,096 patients were receiving hemodialysis in an outpatient clinical setting, 12,243 patients were performing in-home hemodialysis, and 62,275 patients were receiving peritoneal dialysis. At the end of 2019, there were 239,419 patients who had a functioning kidney transplant. Without dialysis or a kidney transplant, the outcome for patients with ESRD is certain death within a short period of time.2

The dialysis industry in the United States is highly concentrated. DaVita’s market share is ~36% while Fresenius has market share of ~38%.3 The industry has been consolidating for over two decades and is effectively a duopoly in many regions. ESRD patients tend to be very sick and rely heavily on outpatient clinics that provide dialysis three times per week for four hours per session. It is important for patients to have safe access to these complex treatments in outpatient clinics that are located a reasonable distance from home. Missed treatments can result in traumatic and expensive hospital admissions, often via the emergency room.

The health care industry, broadly defined, has a number of peculiar characteristics due to heavy government involvement from a regulatory and payment perspective.  In the case of kidney care, government policy plays a particularly important role that must be explored in order to clearly understand the dialysis industry.

After presenting a brief company overview, I focus primarily on DaVita’s dialysis business in the United States which accounts for the vast majority of the company’s revenue and all of its profitability. Understanding the intricacies of the U.S. dialysis business is the key to understanding DaVita’s overall business model.

While DaVita has posted strong free cash flow over many years and has been a major repurchaser of shares, there are a number of risks associated with DaVita’s business in particular and the dialysis industry in general. DaVita has a highly leveraged balance sheet. While debt servicing is not a problem given the current stability of the business, political risks could change the situation for the entire industry.

Finally, I briefly consider the fact that Berkshire Hathaway is a major investor in DaVita and currently owns ~38% of the company.  Is there a chance that Berkshire could acquire DaVita in a friendly transaction?


Company Overview


Copyright, Disclosures, and Privacy Information

Nothing in this newsletter constitutes investment advice and all content is subject to the copyright and disclaimer policy of The Rational Walk LLC.  

Your privacy is taken very seriously. No email addresses or any other subscriber information is ever sold or provided to third parties. If you choose to unsubscribe at any time, you will no longer receive any further communications of any kind.

The Rational Walk is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.

No position in DaVita.
Long Berkshire Hathaway.


DaVita: An Essential Provider of Dialysis Services
  1. Unless otherwise specified, data in this article that is specific to DaVita was taken from the company’s 2021 annual report on form 10-K and the company’s Q1 2022 10-Q, and historical data was taken from the company’s past SEC filings. []
  2. All statistics in the paragraph were taken from the Prevalent ESRD by modality section of the USRDS 2021 Annual Data Report. []
  3. Market share for DaVita is from the company’s 2021 annual report, linked to above. For Fresenius, market share data is from the company’s annual report. []
Tagged on: